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Abstract
Angiogenesis is essential for tumor development and progression. Genetic variation in
angiogenesis-related genes may influence breast carcinogenesis. We evaluated dietary factors
associated with oxidative balance, DDIT4 (1 SNP), FLT1 (35 SNPs), HIF1A (4 SNPs), KDR (19
SNPs), MPO (1 SNP), NOS2A (15 SNPs), TEK (40 SNPs), and VEGFA (8 SNPs) and breast
cancer risk among Hispanic (2111 cases, 2597 controls) and non-Hispanic white (NHW) (1481
cases, 1586 controls) women in the Breast Cancer Health Disparities Study. Adaptive Rank
Truncated Product (ARTP) analysis was used to determine gene and pathway significance with
breast cancer. TEK was associated with breast cancer overall (PARTP = 0.03) and with breast
cancer survival (PARTP = 0.01). KDR was of borderline significance overall (PARTP = 0.07),
although significantly associated with breast cancer in both low and intermediate Native American
(NA) ancestry groups (PARTP = 0.02) and ER+/PR- tumor phenotype (PARTP = 0.008). Both
VEGFA and NOS2A were associated with ER−/PR− tumor phenotype (PARTP = 0.01 and PARTP =
0.04 respectively). FLT1 was associated with breast cancer survival among those with low NA
ancestry (PARTP = 0.009). With respect to diet, having a higher dietary oxidative balance score
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(DOBS) was significantly associated with lower breast cancer risk (OR 0.74 95% CI 0.64–0.84),
with the strongest associations observed for women with the highest NA ancestry (OR 0.44 95
%CI 0.30–0.65). We observed few interactions between DOBS and angiogenesis-related genes.
Our data suggest that dietary factors and genetic variation in angiogenesis-related genes contribute
to breast cancer carcinogenesis.
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Introduction
Angiogenesis, or the development of new blood vessels, is essential for cancer progression
by allowing tumor cells oxygen and nutrients needed for growth [1, 2]. Vascular endothelial
growth factor A (VEGFA) and its receptors are major mediators of tumor angiogenesis [3].
As pro-angiogenic growth factors, VEGFA and its tyrosine kinase receptors, VEGFR-1
(alias FLT1) and VEGFR-2 (alias KDR), promote angiogenesis, vascular permeability, cell
migration and gene expression and have been the target of anti-cancer therapy [1]. VEGF
when released by various cells at the site of inflammation induces angiogenesis [4]. It is
believed that VEGF signaling in angiogenesis is mainly mediated through KDR which
stimulates endothelial cell survival, cell proliferation, migration and invasion, and capillary-
like tube formation [5]. FLT1 is thought to modulate binding of KDR and VEGF.
Endothelial tyrosine kinase (TEK) also known as TIE2, is involved in angiogenesis in
conjunction with growth factors angiopoietin 1 and 2 [6]. Studies have linked TEK
expression to breast cancer metastasis and bone metastasis in particular [7, 8].
Inflammation is closely linked to angiogenesis and a hallmark feature of tumorigenesis as
inflammatory cells that infiltrate tissue can stimulate angiogenesis. One mechanism for this
is the induction of nitric oxide synthase (NOS2) by inflammatory cytokines and hypoxia.
NOS2 produces large amounts of nitric oxide which can increase apoptosis and inhibit
carcinogenesis or promote carcinogenesis by increasing angiogenesis [9]. Hypoxia also can
induce hypoxia-inducible factor-1A (HIFIA), which is a transcription factor involved in the
regulation of the tumor microenvironment [10]. HIFIA has been linked to aggressive tumor
phenotypes by promoting angiogenesis and tumor metastasis and invasion and is modulated
by ROS in response to oxidative stress [11]. DNA Damage-Inducible transcript 4 (DDIT4
alias REDD1), is a HIF1A responsive protein that is induced by adverse environmental
conditions and enhances oxidative stress-dependent cell death. It has been shown to be a
negative feedback regulator of HIF1A that influences HIF1A expression and suppresses
tumorigenesis [12]. Myeloperoxidase (MPO) generates reactive oxidant species as part of its
function in innate host defense mechanisms that can lead to damage of normal tissue and
contribute to inflammatory injury. Polymorphisms in MPO have been implicated in risk of
lung and prostate cancers [13].
In this study we examined the role of genetic variation in a network of genes that play key
roles in angiogenesis and related inflammatory processes in breast cancer risk. Specifically,
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we investigated associations between genetic variation in VEGFA, FLT1, KDR, TEK,
DDIT4, HIF1A, MPO, and NOS2A genes with risk of developing breast cancer in an
admixed population of non-Hispanic white (NHW) and U.S. Hispanic and Mexican women.
We evaluated associations with ER and PR tumor phenotype and survival as well as the
interactive effects with dietary factors that have pro and anti-oxidative properties that could
modify the effects of these genes. These included alcohol, polyunsaturated fat, beta
carotene, alpha tocopherol (vitamin E), vitamin C, dietary fiber, and folic acid. We created a
dietary oxidative balance score (DOBS) as previously described to estimate the dietary
oxidative load derived from these nutrients [14]. We focused on main effects of genetic and
dietary factors as well as their interactive effects to determine how these factors work
together to alter risk of breast cancer risk.
Methods
The Breast Cancer Health Disparities Study includes participants from three population-
based case-control studies, the 4-Corner’s Breast Cancer Study, the Mexico Breast Cancer
Study, and the San Francisco Bay Area Breast Cancer Study [15] who completed an in-
person interview and who had a blood or mouthwash sample available for DNA extraction.
In the 4- Corner’s Breast Cancer Study, participants were between 25 and 79 years of age
with a histological confirmed diagnosis of in situ (n=341) or invasive (n=1492) cancer
between October 1999 and May 2004; controls were selected from the target populations of
cases living in Arizona, Colorado, New Mexico, and Utah and were frequency matched to
cases on ethnicity and 5-year age distribution[16]. Participants from the Mexico Breast
Cancer Study were between 28 and 74 years of age. Eligible cases in Mexico were women
diagnosed with either a new histologically confirmed in situ or invasive breast cancer
between January 2004 and December 2007 at 12 participating hospitals from three main
health care systems; controls were randomly selected from the catchment area of the 12
participating hospitals using a probabilistic multi-stage design and frequency matched to
cases based on 5-year age distribution, membership in health care institution, and place of
residence. The San Francisco Bay Area Breast Cancer Study included women aged 35 to 79
years from the San Francisco Bay Area diagnosed with a first primary histologically
confirmed invasive breast cancer between April 1995 and April 2002; controls were
identified by random-digit dialing (RDD) and frequency-matched to cases based on the
expected race/ethnicity and 5-year age distribution [17, 18]. All participants signed informed
written consent prior to participation and each study was approved by the Institutional
Review Board for Human Subjects at each institution.
Data Harmonization
Data were harmonized across all study centers and questionnaires as previously described
[15]. Women were classified as either pre-menopausal or post-menopausal based on
responses to questions on menstrual history. Women who reported still having periods
during the referent year (defined as the year before diagnosis for cases or before selection
into the study for controls) were classified as pre-menopausal. Center-specific definitions
were used to define post-menopausal women. Women were classified as post-menopausal if
they reported either a natural menopause or If they reported taking hormone therapy (HT)
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and were still having periods or were at or above the 95th percentile of age for those who
reported having a natural menopause (i.e., ≥ 12 months since their last period. This age at
menopause was site specific by ethnicity: 58 for NHW and 56 for Hispanic women from the
4-Corner’s Breast Cancer Study; 54 for the Mexico Breast Cancer Study; and 55 for NHW
and 56 for Hispanic women from the San Francisco Bay Area Breast Cancer Study. Dietary
data were collected using detailed food frequency questionnaires or diet histories in all
centers; the referent period was the year prior to diagnosis for both 4-Corner’s Breast Cancer
Study and the San Francisco Bay Area Breast Cancer Study, while in Mexico it was for a
typical week in the year prior to diagnosis or initial symptoms.
Genetic Data
DNA was extracted from either whole blood or mouthwash samples; 7287 blood-derived
and 634 mouthwash-derived samples were available. Whole Genome Amplification (WGA)
was applied to the mouthwash-derived DNA samples prior to genotyping. A tagSNP
approach was used to characterize variation across candidate genes. TagSNPs were selected
using the following parameters: linkage disequilibrium (LD) blocks were defined using a
Caucasian LD map and an r2=0.8; minor allele frequency (MAF) >0.1; range= −1500 bps
from the initiation codon to +1500 bps from the termination codon; and 1 SNP/LD bin.
Additionally, 104 Ancestral Informative Markers (AIMs) were used to distinguish European
and Native American ancestry in the study population [15]. All markers were genotyped
using a multiplexed bead array assay format based on GoldenGate chemistry (Illumina, San
Diego, California). A genotyping call rate of 99.93% was attained (99.65% for WGA
samples). We included 132 blinded internal replicates representing 1.6% of the sample set.
The duplicate concordance rate was 99.996% as determined by 193,297 matching genotypes
among sample pairs. In the current analysis we evaluated DDIT4 (1 SNP), FLT1 (35 SNPs),
HIF1A (4 SNPs), KDR (19 SNPs), MPO (1 SNP), NOS2A (15 SNPs), TEK (40 SNPs), and
VEGFA (8 SNPs). A description of these genes and SNPs is shown in online Supplement 1.
Tumor Characteristics and Survival—Survival information and ER/PR tumor
information were not available for cases from Mexico and therefore assessment of these
variables is limited to data obtained from the 4-Corner’s Breast Cancer Study and the San
Francisco Bay Area Breast Cancer Study. Cancer registries in Utah, Colorado, Arizona,
New Mexico, and California provided information on stage at diagnosis, months of survival
after diagnosis, cause of death, and estrogen receptor (ER) and progesterone receptor (PR)
status. Information on ER and PR status of tumors was available for 1019 (69%) NHW and
977 (75%) Hispanic cases. Surveillance Epidemiology and End Results (SEER) summary
disease stage was available for breast cancer cases from the U.S. Staging is based on three
codes of local, regional, and distant, where distant corresponds to AJCC stage 4, local is
predominately AJCC stage 1 with some stage 2, and regional contains AJCC stage 2 and 3.
Statistical Methods
Genetic ancestry estimation—The program STRUCTURE was used to compute
individual ancestry for each study participant assuming two founding populations [19, 20].
A three-founding population model was assessed but did not fit the population structure with
the same level of repeatability and correlation among runs as the two-founding population
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model. Participants were classified by level of percent Native American (NA) ancestry.
Assessment across categories of ancestry was done using cut-points based on the
distribution of genetic ancestry in the control population with the goal of creating distinct
ancestry groups that had sufficient power to assess associations. Three strata, 0–28%, 29 to
70%, and 71 to 100%, were used to evaluate associations by level of NA ancestry. Genetic
ancestry was used as a continuous variable when included in the models to adjust for
possible confounding.
SNP Associations—Genes and SNPs were assessed for their association with breast
cancer risk by strata of genetic ancestry and menopausal status in the whole population and
by ER/PR status for the San Francisco Bay Area and 4-Corners studies. All statistical
analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC). Logistic
regression models were used to estimate odds ratios (OR) and 95% confidence intervals (CI)
for breast cancer risk associated with SNPs, adjusting for age, study center, genetic ancestry,
reference year BMI, and parity. Associations with SNPs were assessed assuming a co-
dominant model. Based on the initial assessment, SNPs which appeared to have a dominant
or recessive mode of inheritance were evaluated with those inheritance models in
subsequent analyses. For stratified analysis test for interactions were calculated using a
Wald 1 df test; adjustments for multiple comparisons within the gene used the step-down
Bonferroni correction (i.e., Holm method) taking into account the correlated nature of the
data using the SNP spectral decomposition method proposed by Nyholt [21] and modified
by Li and Ji [22].
Dietary Analysis—Given the hypothesized pathway we evaluated nutrients with anti- or
pro-oxidative balance properties. A dietary oxidative balance score (DOBS) was created
based on each individual’s ranking of each nutrient included in the score. Anti-oxidants
included were vitamin C, vitamin E, beta carotene (data for beta carotene was not available
for Mexico), folic acid, and dietary fiber; alcohol was treated as a pro-oxidant. To account
for the different number of foods queried on the diet questionnaires used for each study,
nutrients were evaluated as nutrient per 1000 calories and quartiles of intake and the DOBS
were based on study-specific distributions; additional adjustment for calories did not alter
findings. Long-term alcohol consumption was classified into three levels: the top 25th
percentile of consumption, all other drinkers, and non-drinkers. In creating the DOBS,
participants were assigned values of zero for low levels (first quartile) of exposure to anti-
oxidants or high exposure to pro-oxidants (fourth quartile), one for intermediate levels
(second and third quartiles) of exposure, and two for high levels (fourth quartile) of
exposure to anti-oxidants and low exposure (first quartile) to pro-oxidants. We report ORs
and 95% CI for each component part of the DOBS as well as associations for the overall
summary score. DOBS trend p values and p values for interaction between the DOBS and
SNPs were based on one degree of freedom (1-df) Wald chi-square test statistics as noted
above.
Survival Analysis—Survival months were calculated based on month and year of
diagnosis and month and year of death or date of last contact by SEER registry; all registry
updates were through the spring of 2012. Associations between SNPs and risk of dying of
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breast cancer among primary invasive cases were evaluated using Cox proportional hazards
models to obtain multivariate hazard ratios (HR) and 95% CI by admixture strata. Since
survival data were not available for the Mexico study site, the upper two admixture strata
were combined to evaluate survival by ancestry groups. Individuals were censored when
they died of causes other than breast cancer or were lost to follow-up. In addition to the
minimal adjustments for age, study center, genetic ancestry, referent year BMI, and parity,
models were also adjusted for SEER summary stage to estimate the HR. Interactions
between genetic variants and genetic ancestry with survival were assessed using p values
from 1-df Wald chi-square tests.
ARTP analysis—We used the adaptive rank truncated product (ARTP) method that
utilizes a highly efficient permutation algorithm to determine the significance of association
of each gene and of the angiogenesis pathway with breast cancer overall, by admixture, and
by ER/PR strata. The gene p values were generated using the ARTP package in R,
permuting outcome status 10,000 times while adjusting for age, reference year BMI, and
genetic admixture [23, 24]. We also controlled for SEER summary stage when estimating
the ARTP for breast cancer survival. We report both pathway and gene p values (PARTP).
The original R program was modified to incorporate Cox Proportional Hazard modeling that
permuted both vital status and survival months to estimate gene and pathway associations.
Results
The majority of breast cancer cases were Hispanic, under 60 years of age, and post-
menopausal (Table 1). Among U.S. cases, most tumors were ER+/PR+. ER−/PR− tumors
accounted for 18.4% of NHW and 23.4% of Hispanic cases. The majority of women who
self-reported being NHW were estimated as having low NA Ancestry (99.5% of controls),
while U.S. women who self-reported being Hispanic where divided between those with
intermediate NA ancestry (64.9% of controls) and high NA ancestry (24.4% of controls).
Intake of alcohol was very low in the study population and significantly lower among NHW
and Hispanic controls than cases. Among women who self-reported being Hispanic or were
from Mexico, median levels of all nutrients, except for vitamin C, were significantly
different between cases and controls; no significant associations were observed for
individual nutrients for NHW women.
Associations between genes and breast cancer risk overall and by admixture group showed
that several genes in the pathway were statistically significantly associated as determined by
ARTP (SNPs that showed statistical significant for KDR, NOS2A, TEK are shown in Table
2), whereas other genes, such as FLT1 had several significant SNPs that did not maintain
statistical significant using ARTP (Online Supplement Table 2). When considering all
women together, TEK was associated with breast cancer risk (PARTP= 0.03) while KDR was
of borderline significance (PARTP = 0.07). When stratified by NA ancestry, KDR was
significantly associated with breast cancer risk among women in the low and middle NA
ancestry groups (PARTP = 0.02 and 0.02 respectively), this reflects the strong association
observed for rs12498529 and modest associations with both rs2219471 and rs1531290. Both
NOS2A and KDR were associated with breast cancer risk in the middle NA ancestry group
(PARTP = 0.04 and 0.02 respectively); KDR rs12498529 remained statistically different
Slattery et al. Page 6






















between admixture groups after adjustment for multiple comparisons (Padj = 0.03). The
significant gene associations as determined by ARTP reflect both the numbers of SNPs
associated within a gene as well as the strength of the SNP associations. For KDR, these
include rs12498529, rs203465, and rs1531290; for NOS2A, these include rs7406657 and
rs2297516. No genes were significantly associated in the highest NA ancestry group as
determined by ARTP. The overall pathway PARTP was 0.25. Associations did not differ by
menopausal status.
Four genes were associated with various ER/PR tumor sub-groups as determined by ARTP
(Table 3). KDR was associated with ER+/PR- tumors with seven SNPs having significant
associations with this tumor type (PARTP = 0.0008). NOS2A was associated with ER−/PR−
tumors (2 SNPs) as was VEGFA (3 SNPs) (PARTP = 0.04 and 0.01 respectively). TEK was
associated with ER+/PR+ tumors (PARTP = 0.048) having 4 SNPs significantly associated.
TEK was of borderline significance (PARTP = 0.06 with ER−/PR+ tumors). Several SNPs in
FLT1 were associated with specific tumor phenotype, however the gene p value from ARTP
was >0.05 for all tumor phenotypes (associations shown in online Supplemental Table 3).
Given the biological plausibility that dietary factors with pro- and anti-oxidant properties
could modify breast cancer risk associated with angiogenesis-related genes, we evaluated
dietary factors that have recognized pro- or anti-oxidant properties. Several of these factors
were statistically significantly associated with breast cancer overall and by admixture groups
(Table 4). These include alcohol, vitamin E, beta carotene, folic acid, dietary fiber, and the
summary DOBS. For the most part, associations were strongest among women with the
highest level of NA ancestry. For instance, highest level of alcohol intake was only
associated with an increased risk among women with the highest NA ancestry, while
vitamin E, folic acid, and the dietary oxidative balance score were more associated with
decreased risk (DOBS interaction p value = 0.001). No association was observed for vitamin
C for all groups.
Significant interaction was observed between the DOBS and the following SNPs: FLT1
rs7987649; KDR rs1531289; TEK rs669102, rs12350649, rs17834811, rs7047856, and
rs581724; and VEGFA rs3025033, although after adjustment for multiple comparisons only
the VEGFA rs3025033 remained statistically significant (Padj=0.03) (Table 5). The
protective association observed for having a high DOBS was observed for all genotypes,
however, the magnitude of that association differed by genotypes, and in some instances
such as TEK rs17834811, rs7047856, and rs581724 there was no additional reduction in risk
beyond that observed for the homozygote variant genotype group.
Angiogenesis genes also were associated with survival (Figure 1), however only KDR
(PARTP = 0.04), and TEK (PARTP = 0.02) showed statistically significant p values for the
association as estimated by ARTP and FLT1 was of borderline significance (PARTP =
0.052). FLT1 also was significantly associated with breast cancer survival among those
women with the lowest level of NA ancestry (PARTP = 0.009) with the pathway p value
among this group being 0.09. As shown in Figure 1, both of these genes had several SNPs
that were associated with survival overall and within specific ancestry groups. The overall
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pathway PARTP for survival was 0.06. Only DDIT4 was of borderline significance among
those with NA ancestry over 28% (PARTP = 0.07).
Discussion
Angiogenesis-related genes were associated with both breast cancer development and
progression in this population of NHW and Hispanic/Mexican women. Some associations
appeared stronger for specific tumor phenotype and others appeared to interact with dietary
factors associated with oxidative balance. Of the genes assessed, TEK appeared to influence
breast cancer the most, as seen by its association with breast cancer risk and survival. KDR,
NOS2A, and VEGFA were associated with breast cancer for specific tumor phenotypes,
while FLT1 was associated with survival among women who were primarily NHW. We did
not observe differences in association by menopausal status and most associations were
strongest in groups that did not include high NA ancestry.
Angiogenesis is an essential component of the carcinogenic process. Increased
vascularization allows tumors to obtain the necessary nutrients and oxygen needed for
growth and invasion. As such, angiogenesis-related genes are potentially important in
regulating breast cancer development and progression. Studies have evaluated angiogenesis
genes with mixed results. VEGFA has been the focus of much research because of its well-
documented role in angiogenesis and its potential as a treatment modality for cancer
patients. Several polymorphisms have been associated with breast cancer. The Cancer
Prevention Study II cohort examined three polymorphisms and found an association with
invasive breast cancer for −2578 (rs699947) and −1154 (rs1570360) [25]. The −2578
polymorphism also was associated with increased breast cancer risk in a study of African
American women by Schneider [26] but not in one by Langsenlehner [27] or Jin [28]. The
+936 (rs3025039) was not associated with breast cancer risk in a study conducted by
Oliveira [29], Balasubramanian [30], Langsenlehner [27], although Krippl [31], Rodrigues
[32] , and Kataoka [33] saw an inverse association with the TT genotype. We did not
observe a significant association with this polymorphism. Likewise, we did not observe a
significant association for VEGFA rs25648 similar to what has reported by Langsenlehner
[27]; Balasubramanian [30] only observed a significant association with survival. We only
observed an association between VEGFA rs25648 and ER−/PR− tumors but not with breast
cancer survival. Beeghly-Fadiel and colleagues in their study of Chinese women saw an
increased risk with VEGFA rs833070 and FLT1 rs9551471; we did not see an increased risk
with either of these polymorphisms. We also did not observe an association between breast
cancer survival and VEGFA.
Our findings suggest that VEGFA receptors may play a more important role in breast cancer
carcinogenesis than VEGFA itself. KDR, a type 2 receptor, is primarily responsible for
VEGF signaling in the angiogenesis process; VEGFA has been shown to induce tumor cell
proliferation via activation of KDR [3]. Studies also have shown that drugs that inhibit
VEGF signaling reduce phosphorylated VEGFR2 expression in patients with inflammatory
breast cancer [34]. KDR was significantly associated with breast cancer for all groups except
the highest NA ancestry group. It also was significantly associated with ER+/PR- tumors
and was of borderline significant (PARTP= 0.07) for overall survival. The VEGFA type 1
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receptor, FLT1, was significantly associated with survival among those with low NA
ancestry. The role of FLT1 in angiogenesis is less well defined [3] although several studies
have shown that FLT1 stimulates tumor growth [2]. Our data suggest that FLT1 may be a
tumor promoter, enhancing metastasis, given our observed association with survival.
TEK appeared to have the greatest overall impact on breast cancer in this population. It was
associated with breast cancer risk overall as well as risk of dying from breast cancer after
diagnosis. The strongest associations were for ER+/PR+ tumors, which represent the
majority of breast cancer tumors. TEK regulates angiogenic growth factors, is a receptor for
angiopoietin-1 and 2 (Ang1 and Ang2), and has been have linked to breast cancer metastasis
including bone metastasis [7, 8]. The angiopoietin/TEK pathway is critical to the developing
vasculature and vessel stabilization [35]. Recent studies also have shown the importance of
TEK expression in distinct tie expressing monocytes, or TEMs, that play a key role in tumor
promotion and angiogenesis [36, 37]. These TEMs cluster in hypoxic areas of solid tumors
and migrate in response to angiopoietin-2, which modulate TEK-dependent signaling and
regulates apoptosis [38].
Of the genes that could influence angiogenesis through their role in hypoxia and oxidative
stress, only NOS2A was associated with breast cancer risk and only among women with
intermediate NA ancestry and those with ER−/PR− tumors. Nitric oxide can affect cancer
through many ways. It can increase apoptosis and inhibit carcinogenesis or promote
carcinogenesis through increasing angiogenesis [9]. While we had hypothesized that NOS2A
and HIF1A would interact with dietary antioxidants to alter breast cancer risk, as has been
shown in other cancers [14], we did not observe the same level of association in this study.
However, dietary pro- and anti-oxidants were associated with breast cancer risk, especially
among those with greater NA ancestry. While many nutrients had a strong association with
breast cancer and the overall DOBS showed that those who consumed a diet that was high in
anti-oxidants and low in pro-oxidants had a reduced risk of breast cancer, the influence of
genetic factors on these associations was minimal. This suggests that oxidative processes are
important and that dietary intake may play an important and robust role in this process
despite genetic variation in related pathways.
The Breast Cancer Health Disparities Study has strengths, in that it is the largest collection
of breast cancer cases of Hispanic and Mexican women reported to date. Additionally, we
utilized information on genetic admixture to more accurately define NA ancestry and
capture heterogeneity among Hispanics. All three contributing data sites collected extensive
diet and lifestyle data, allowing us to utilize harmonized data to assess main effects as well
as interaction with genes. While we were able to evaluate tumor phenotype and survival in
the U.S. studies, we did not have those data available from Mexico. Thus, data on ER and
PR tumor status and survival do not have the range of NA ancestry that is included in the
main effect risk estimates and dietary associations. A smaller sample to evaluate these
associations can also contribute to less power, which could limit our ability to detect some
associations, especially for rarer variants. Additionally we lack complete treatment data
which prohibits us from evaluating associations with these genes stratified by type of
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treatment, which could be informative. Studies that focus on determining functionality of
SNPs within these genes could importantly add to this work.
In summary, our data suggest that angiogenesis-related genes are important in both breast
cancer risk and survival. Genetic variation in the tyrosine kinase receptors, TEK, KDR, and
FLT1 appear to have the most effect on disease risk and survival and thus these genes may
be candidates for drug therapy targets. While dietary antioxidants were associated with
breast cancer risk, the genes evaluated had little modifying effect on observed associations
with diet. The findings from this study support the importance of these genes in breast
cancer carcinogenesis and should be replicated in other population-based studies.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Hazard ratios and 95% confidence bounds of angiogenesis-related genes associated with
breast cancer survival
A=Additive model, D=Dominant Model, R= Recessive Model; p values are for ARTP
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